ReviewExperimental & molecular medicine2026
Hematopoietic stem cell aging: a review of transcriptional and multi-omics insights and potential paths for AI integration.
Review in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematopoietic stem cell (HSC) aging underlies age-related immune decline, anemia and increased risk of hematologic malignancies, including clonal hematopoiesis and leukemia. Many available microarray and bulk RNA sequencing studies have elucidated conserved transcriptional hallmarks, such as myeloid bias, inflammation dysregulation, and self-renewal reinforcement in aged HSCs across mouse and human models. Here, we review key publicly available transcriptome and epigenome datasets from landmark studies, highlighting their contributions to defining HSC molecular aging signatures. We also summarize recent single-cell RNA sequencing, HSC aging intervention, and sex difference datasets. Despite these advances in technology and available sequencing datasets, fragmented data access, limited cross-species integration, and scarcity of multi-omics and single-cell contexts hinder progress. We discuss strategies for dataset harmonization, incorporation of multi-omics (transcriptome, epigenome, and proteome) and single-cell resolution to uncover heterogeneity and trajectories, as well as introduce the application of artificial intelligence and machine learning for predictive modeling, epigenome aging clocks, variant calling, clonal hematopoiesis detection, chromatin-based age prediction, and trajectory inference. Bridging insights from genetic mutant mouse models to emerging human bone marrow organoids offers translational potential for modeling HSC aging in vitro. We propose a curated, centralized, interactive database as a community resource to integrate these layers, enabling meta-analyses, artificial intelligence-driven discoveries, and accelerated therapeutic interventions for age-related hematopoietic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.